PRFX (PainReform) Cash-to-Debt : 94.69 (As of Dec. 2024)

View and export this data going back to 2020. Start your Free Trial

What is PainReform Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. PainReform's cash to debt ratio for the quarter that ended in Dec. 2024 was 94.69.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, PainReform could pay off its debt using the cash in hand for the quarter that ended in Dec. 2024.

The historical rank and industry rank for PainReform's Cash-to-Debt or its related term are showing as below:

PRFX' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.01 Med: 94.69 Max: No Debt
Current: 94.69

During the past 7 years, PainReform's highest Cash to Debt Ratio was No Debt. The lowest was 0.01. And the median was 94.69.

PRFX's Cash-to-Debt is ranked better than
87.69% of 1007 companies
in the Drug Manufacturers industry
Industry Median: 1.02 vs PRFX: 94.69

PainReform Cash-to-Debt Historical Data

The historical data trend for PainReform's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

PainReform Cash-to-Debt Chart

PainReform Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Cash-to-Debt

Get a 7-Day Free Trial

No Debt

93.33

94.69

PainReform Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Dec24
Cash-to-Debt	Get a 7-Day Free Trial															91.28	93.33	60.06	47.17	94.69

Competitive Comparison of PainReform's Cash-to-Debt

For the Drug Manufacturers - Specialty & Generic subindustry, PainReform's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

PainReform's Cash-to-Debt Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, PainReform's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where PainReform's Cash-to-Debt falls into.

Save Embed

;

Save Embed

;

PainReform Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

PainReform's Cash to Debt Ratio for the fiscal year that ended in Dec. 2024 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	4.261	/	(0.045	+	0)
	=	94.69

PainReform's Cash to Debt Ratio for the quarter that ended in Dec. 2024 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	4.261	/	(0.045	+	0)
	=	94.69

PainReform (NAS:PRFX) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

PainReform Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of PainReform's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

PainReform Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » PainReform Ltd (NAS:PRFX) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

65 Yigal Alon Street, Tel Aviv, ISR, 6744316

Website

https://www.painreform.com

PainReform Ltd is a clinical-stage specialty pharmaceutical company. It is focused on the reformulation of established therapeutics. The company's product PRF-110 is based on the local anesthetic ropivacaine, targeting the post-operative pain relief market. PRF-110 is an oil-based, viscous, clear solution that is deposited directly into the surgical wound bed before closure to provide localized and extended post-operative analgesia.